Authors

Latest:

Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Philippe Ruszniewski, MD

Latest:

Dr. Philippe Ruszniewski on NETTER-1 Study Results

Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase 3 NETTER-1 study.

Phillip J. Koo, MD

Latest:

Dr Koo on the Clinical Utility of PSMA PET in Prostate Cancer

Phillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.

Phillip Koo, MD, MD Anderson Cancer Center

Latest:

Advances in Nonmetastatic CRPC

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

Phillip Scheinberg, MD, Hospital Sao Jose

Phillippe Moreau, MD

Latest:

Dr. Moreau on the CASSIOPEIA Trial in Transplant-Eligible Myeloma

Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

Phyllis McKiernan

Latest:

Autologous Stem Cell Transplantation in Multiple Myeloma

Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses the outcomes of a study investigating autologous stem cell transplantation (ASCT) in elderly patients with multiple myeloma.

Physician Editor

Latest:

Highlights from Two Key Symposiums: Reporting on new research and emerging trends in breast and liver cancer.

Reporting on new research and emerging trends in breast and liver cancer.

Pier Luigi Filosso, MD

Latest:

Dr. Filosso on Future of Treating Patients With Lung NETs

Pier Luigi Filosso, MD, associate professor of Thoracic Surgery, University of Torino, Italy, discusses future approaches to treating patients with neuroendocrine tumors of lung origin.

Pier Luigi Zinzani, MD, PhD, University of Bologna

Pier Luigi Zinzani, MD, PhD, University of Bologna Institute of Hematology

Pierfranco Conte, MD

Latest:

Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Pierluigi Porcu, MD,

Latest:

Dr. Porcu on the Need for Diverse Representation in Clinical Trials

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

Pierre Gholam, MD, UH Westlake Health Center

Latest:

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Pieter Sonneveld, MD, PhD

Latest:

Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed Myeloma

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Pieternella J. Lugtenburg, MD, PhD

Latest:

Dr. Lugtenburg on Maintenance Rituximab in DLBCL

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.

Pinkal Desai, MD, MPH

Polly Mazanec, PhD, ACNP, AOCN, FPCNÂ

Latest:

Managing Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.

Pooja Murthy, MD

Latest:

Integrating PARP Inhibitors Into the Treatment of Women

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Prachi Patel-Predd

Latest:

News Reports: April 2007

News reports featured in this issue: 1) Breast Cancer Spotlight 2) Expert Cancer Centers Cost-Effective for Managing Ovarian Cancer 3) New Breathalyzer